KOS 2187

Drug Profile

KOS 2187

Alternative Names: KOS-2187; PF-04548043; PF-4548043

Latest Information Update: 14 May 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kosan Biosciences
  • Developer Pfizer
  • Class Gastrokinetics
  • Mechanism of Action Motilin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux

Most Recent Events

  • 17 Oct 2008 Updated MoA
  • 27 Jun 2008 Kosan has been acquired by Bristol-Myers Squibb
  • 06 Aug 2007 Phase-I clinical trials in Diabetic gastroparesis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top